The Traderszone Network

3 July, 2021 by The TZ Newswire Staff Comments Off on Have You Done Enough to Avoid the Crisis in Retirement Planning?

Have You Done Enough to Avoid the Crisis in Retirement Planning?

Harvard Business Review (HBR) published a dire warning seven years ago. Most Americans don’t know how to execute a retirement strategy that addresses the most prominent risk-income insecurity. With fewer people receiving guaranteed income from pension plans, we’ve been forced to rely on our own planning to take care of cash needs in retirement. How can you ensure that you don’t run out of money in retirement and that you’ll have enough income each month to pay all of your bills?

read more

3 July, 2021 by The TZ Newswire Staff Comments Off on Could This Recently IPOed Medical Device Maker Make You Rich?

Could This Recently IPOed Medical Device Maker Make You Rich?

NeuroPace (NASDAQ: NPCE), is growing the implantable device market for treating drug-resistant focal epilepsy and setting itself up to dominate it for years to come. With an offering that provides better outcomes than its competition, significant penetration into epilepsy centers across the U.S., and potential label expansions that could just about double its current addressable market, this company could offer significant upside to investors.

read more

3 July, 2021 by The TZ Newswire Staff Comments Off on How Does Real Estate Perform During Inflation?

How Does Real Estate Perform During Inflation?

Is your house an investment? With housing prices on the rise, it sure seems like it is. But over the long run, it’s a different story. On a Motley Fool Live episode recorded on June 17, Motley Fool contributor Matthew Frankel discusses the performance of housing returns over the long term and how it compares with inflation. 

Continue reading

3 July, 2021 by The TZ Newswire Staff Comments Off on What Are the Odds That Vertex Strikes a Big Acquisition Deal?

What Are the Odds That Vertex Strikes a Big Acquisition Deal?

Vertex Pharmaceuticals (NASDAQ: VRTX) certainly has the cash to acquire smaller biotechs. However, there’s also a possibility that the company could be an acquisition target itself. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli discuss what the odds are that Vertex is involved in a big acquisition within the next few years.

read more